AUTL
Autolus Therapeutics plcNASDAQHealthcare$1.41+2.17%ClosedMarket Cap: $375.3M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.08
P/S
4.91
EV/EBITDA
-2.47
DCF Value
$-28.20
FCF Yield
-83.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
-27.8%
Operating Margin
-358.9%
Net Margin
-381.4%
ROE
-99.0%
ROA
-48.8%
ROIC
-51.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $24.3M | -4.3% | $-72.4M | $-90.2M | $-0.34 | — |
| FY 2025 | $75.6M | -27.8% | $-281.4M | $-287.5M | $-1.08 | — |
| Q3 2025 | $21.2M | -35.1% | $-71.6M | $-79.1M | $-0.30 | — |
| Q2 2025 | $20.9M | -16.8% | $-61.2M | $-47.9M | $-0.18 | — |
| Q1 2025 | $9.0M | -99.9% | $-65.2M | $-70.2M | $-0.26 | — |
| Q4 2024 | $29.0K | -476810.3% | $-241.4M | $-27.6M | $-0.10 | — |
| FY 2024 | $10.1M | -1293.5% | $-241.4M | $-220.7M | $-0.87 | — |
| Q3 2024 | $0.00 | -Infinity% | $-68.9M | $-82.1M | $-0.31 | — |
| Q2 2024 | $0.00 | NaN% | $-58.9M | $-58.3M | $-0.22 | — |
| Q1 2024 | $10.1M | 82.1% | $-38.8M | $-52.7M | $-0.24 | — |
| Q4 2023 | $0.00 | -Infinity% | $-40.9M | $-77.2M | $-0.44 | — |
| FY 2023 | $1.7M | 100.0% | $-179.7M | $-208.4M | $-1.20 | — |